Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
LP-935509 is an inhibitor of AP2-associated protein kinase 1 (AAK1) and BMP2-inducible kinase (BMP2K; IC50s = 3.3 and 14 nM, respectively).1 It is selective for AAK1 and BMP2K over μ- and κ-opioid, as well as α2A- and α2C-adrenergic, receptors (IC50s = >30 µM for all), α1 and α2 subunit-containing GABAA receptors (IC50s = 12 µM for both), and cyclin G-associated kinase (GAK; IC50 = 0.32 µM). LP-935509 (1 µM) reduces phosphorylation of the synaptic vesicle regulator AP2 complex subunit Μu-1 (AP2M1) in SH-SY5Y neuroblastoma cells.2 It reduces the number of formalin-induced flinches in mice when administered at doses of 10, 30, and 60 mg/kg.1
WARNING This product is not for human or veterinary use.
1. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain. J. Pharmacol. Exp. Ther. 358(3), 371-386 (2016).
2. Dysregulation ofthe AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration. Sci. Signal. 14(693), eabg3555 (2021).